Integration of Nano-Molecular Imaging and Nanosensors

项目4/Gambhir Pi：Gambhlr，Sanjiv S N3.4.1。项目摘要。我们的长期目标是将纳米诊断技术(体外和体内)转化为临床，以改善癌症患者的管理。我们的主要关注点是开发和使用纳米技术，用于早期癌症检测/干预，以及监测抗肿瘤治疗的反应。在目前的提案中，我们将重点放在卵巢癌和非小细胞肺癌上，但预计我们的策略最终将适用于许多其他癌症。在上一轮CCNE竞争续期拨款中，我们已经取得了重大进展，包括开发了拉曼和光声分子成像策略。在过去的一年里，我们还致力于将基于金的拉曼纳米颗粒与内窥镜成像相结合，用于患者早期结直肠癌的检测。 我们将利用体外纳米传感器和体内纳米分子成像来实现我们的长期目标。体外和体内诊断策略的结合有望比单独使用任何一种策略都能带来更高的准确性和成本效益。为了翻译我们的体外和体内诊断策略，我们将利用人类癌症的小鼠模型，帮助我们在临床翻译之前测试我们的方法。临床翻译将通过临床翻译核心(核心3)的帮助完成，该核心链接到各种临床试验，并利用我们CCNE中已有的其他资助机制。为了实现我们的目标，将追求卵巢癌和非小细胞肺癌诊断的两个目标，并将在下一步详细说明(图3)。N3.4.1)。

PROJECT 4/GAMBHIR PI: Gambhlr, Sanjiv S N3.4.1. Project Summary. Our long-term goals are to clinically translate nanodiagnostics {in vitro and in vivo) for the improved management of cancer patients. Our primary focus for this competing GONE renewal is on developing and using nanotechnology for earlier cancer detection/intervention, and for monitoring response to anti-neoplastic therapy. In the current proposal we focus on both ovarian and non-small cell lung cancers but expect that our strategies will eventually apply to many other cancers. We have made significant progress over the last cycle of this CCNE competing renewal grant including the development of Raman and photoacoustic molecular imaging strategies. In the last year we have also pursued translation of gold based Raman nanoparticles with endoscopic imaging for earlier colorectal cancer detection in patients. Both in vitro nanosensors and in vivo nano-molecular imaging will be utilized to accomplish our long-term goals. The combination of both in vitro and in vivo diagnostic strategies is expected to lead to a much greater accuracy and cost-effectiveness than either strategy alone. To translate our in vitro and in vivo diagnostic strategies we will utilize mouse models of human cancer that help us to test our approaches prior to clinical translation. The clinical translation will be accomplished through the help ofthe clinical translation core (Core 3) which links to various clinical trials and leverages on other funding mechanisms already in place in our CCNE. Two aims focused on ovarian and non-small cell lung cancer diagnostics will be pursued to accomplish our goals and are detailed next (Fig. N3.4.1).